Abstract:AIM: To investigate the inhibitory effects of endostatin-vascular endothelial growth inhibitor (VEGI(151)) recombinant adenoviruses on neovascularization.METHODS: We used recombinant adenoviruses to treat human vascular endothelial cell line ECV304, human hepatocellular carcinoma cell line HepG2, and murine fibroblast cell line L929, in order to study the chimeric gene expression in these cell lines. Chick choriallantic membrane (CAM) model, rabbit inflammatory corneal neovascularization (CNV) model, and liver cancer-bearing nude mice model were employed to investigate the negative biological effect of fusion molecules on neovascularization in vivo.RESULTS: Western blot showed that the molecular weight of fusion protein was about 41kD after infection of ECV304, HepG2 and L929 cells with supernatant of AdhENDO-VEGI(151). The fusion protein showed a specific inhibitory effect on the proliferation of ECV304 cells, but no inhibitory effect on the growth of HepG2 and L929 cells (F=13112.13, P=0.0001). In the chick choriallantic membrane (CAM) assay, the expressed fusion protein significantly inhibited neovascularization. Rabbit inflammatory corneal neovascularization (CNV) induced by intrastromal sutures resulted in a uniform neovascular response. In this model, direct subconjunctival injection of AdhENDO-VEGI(151) expressed the fusion protein in vivo and suppressed the development of CNV. Topical application of AdhENDO-VEGI(151) led to a significant suppression of CNV (F=1413.11, P=0.0001), as compared with the control group of AdLacZ. Immunohistochemical staining showed the fusion protein dominantly expressed in corneal epithelium. Compared with the control group of AdLacZ (4075.9 +/- 1849.9 mm(3)), the average tumor size of group AdhENDO-VEGI(151) reduced in size (487.7 +/- 241.2 mm(3)) (F=14.80, P=0.0085), with an inhibition rate of 88.03%. Immunohistochemical staining showed the adenoviruses carried the fusion gene expressed on liver cancer cell membrane. MVD decreased more significantly in treated mice (30.75 +/- 3.31%) than in AdLacZ control (50.25 +/- 8.65%) (F=17.72, P=0.0056) with an inhibition rate of 39%.CONCLUSION: Fusion protein expressed by recombinant adenoviruses has a significant inhibitory effect on neovascularization.

In Vitro Study on Combination of Oncolytic Adenovirus and Ad - Endo Against Cervical Carcinoma

Combined Use of Chemotherapeutics and Oncolytic Adenovirus in Treatment of AFP-expressing Hepatocellular Carcinoma

Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Oncolytic Adenovirus Zd55-Trail As A Therapy Against Cervical Cancer

Therapeutic effect of endostatin-vascular endothelial growth inhibitor recombinant adenoviruses on gastric carcinoma in nude mice

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Effects of Endostatin-Vascular Endothelial Growth Inhibitor Chimeric Recombinant Adenoviruses on Antiangiogenesis

[The Effect of Oncolytic Adenovirus on Human Umbilical Vein Endothelial Cell].

Recombinant Oncolytic Adenovirus Combined with Cyclophosphamide Induces Synergy in the Treatment of Breast Cancer in Vitro and in Vivo

[Adenovirus-Mediated PDCD5 Gene Transfer Sensitizes Apoptosis of K562 Cells Induced by Etoposide].

Inhibitory Effect of Adeno-Associated Virus-Mediated Gene Transfer of Human Endostatin on Hepatocellular Carcinoma

E10A, an Adenovirus Carrying Human Endostatin Gene, in Combination with Docetaxel Treatment Inhibits Prostate Cancer Growth and Metastases

Combination Effect of Oncolytic Adenovirus Therapy and Herpes Simplex Virus Thymidine Kinase/ganciclovir in Hepatic Carcinoma Animal Models.

Synergistic Killing Effect of the Conditionally Replicating Adenoviruses Carrying Programmed Cell Death 5 Gene and Etoposide on K562 Cells

Effect of recombinant adenovirus-mediated endostatin-soluble vascular endothelium growth inhibitor fusion gene on corneal neovascularization

[Adenovirus-Delivered Tissue Inhibitor of Metalloproteinases-3 Transfection Increases the Sensitivity of Cervical Cancer Cells to Cisplatin].

The Inhibitory Effect of Conditionally Replicating Adenovirus Combined with Mitomycin on the Proliferation of Bladder Cancer Cells

A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors.

A comparative study of the ability of recombinant oncolytic adenovirus, doxorubicin and tamoxifen to inhibit the proliferation of breast cancer cells

Experimental Study on Adenovirus-Mediated Transfer of P53 or Adenovirus-Mediated Transfer of P53 Combined with Radiotherapy for Human Cervical Cancer Cell Line HeLa Cells

Adenovirus-Mediated Combined Anti-Angiogenic and Pro-Apoptotic Gene Therapy Enhances Antitumor Efficacy in Hepatocellular Carcinoma